A single dose of Janssen Pharmaceuticals' Stelara induced clinical remission in patients with moderate to severe ulcerative colitis, according to data presented at the ACG 2018, Oct. 5-10 in Philadelphia.
Here's what you should know:
1. Researchers conducted a phase 3 study examining the effects of a single intravenous dose of Stelara.
2. About 961 patients were enrolled in the study, receiving either a single IV dose of a placebo, 130 mg of Stelara or around 6 mg/kg of Stelara, depending on their weight.
3. About 15.6 percent of the 130 mg patients and 15.5 percent of the weight-based patients achieved clinical remission.
4. About 26.3 percent of the 130 mg patients and 27 percent of the weight-based patients experienced endoscopic healing.
5. Both Stelara dosage groups made statistically significant improvements in the Inflammatory Bowel Disease Questionnaire.
Janssen Research and Development Vice President of Clinical Development Philippe Szapary, MD, said, "These induction data from the [phase 3] study underscore the potential for this pathway in the treatment of UC, which may lead to a new effective and safe treatment option for UC patients in the future."